Table 2.

Joint effects survival analysis of clinical factors and the DEMs’ signature risk score with OS in HCC patients

Group	Risk score	Variables	Events/total (n = 370)	MST (days)	Crude HR (95% CI)	Crude P	Adjusted HR (95% CI)	Adjusted P£
		Tumor stagea
A	Low risk	Stage I	14/100	NA	1		1
B	Low risk	Stage II	6/38	3258	1.259 (0.535–2.963)	0.598	1.265 (0.537–2.979)	0.59
C	Low risk	Stage III+IV	13/34	1622	1.888 (0.888–4.012)	0.099	1.894 (0.891–4.027)	0.097
D	High risk	Stage I	28/71	1372	2.182 (1.181–4.031)	0.013	2.160 (1.169–3.992)	0.014
E	High risk	Stage II	20/47	848	2.547 (1.368–4.743)	0.003	2.525 (1.356–4.702)	0.004
F	High risk	Stage III+IV	35/56	419	5.342 (3.112–9.170)	<0.001	4.857 (2.783–8.457)	<0.001
		Histologic gradeb
a	Low risk	G1	8/37	2131	1		1
b	Low risk	G2	18/95	3125	1.063 (0.512–2.207)	0.869	1.107 (0.496–2.472)	0.803
c	Low risk	G3+G4	10/49	NA	0.492 (0.178–1.357)	0.171	0.559 (0.193–1.618)	0.283
d	High risk	G1	10/18	581	2.029 (0.886–4.648)	0.094	1.752 (0.685–4.483)	0.242
e	High risk	G2	42/82	802	2.289 (1.126–4.655)	0.022	1.970 (0.888–4.371)	0.095
f	High risk	G3+G4	38/84	899	2.431 (1.207–4.897)	0.013	2.183 (1.001–4.760)	0.0496
		Serum AFPc
I	Low risk	≤400 ng/mL	20/121	2532	1		1
II	Low risk	>400 ng/mL	6/26	NA	0.622 (0.189–2.049)	0.435	0.439 (0.105–3.403)	0.262
III	High risk	≤400 ng/mL	42/92	1149	2.243 (1.355–3.712)	0.002	1.982 (1.154–3.403)	0.013
IV	High risk	>400 ng/mL	16/38	2486	1.990 (1.105–3.584)	0.022	1.762 (0.945–3.283)	0.075
		Microvascular invasiond
i	Low risk	No	23/119	3125	1		1
ii	Low risk	Yes	11/50	3258	1.022 (0.476–2.191)	0.956	0.727 (0.298–1.774)	0.484
iii	High risk	No	37/87	1372	2.319 (1.381–3.894)	0.001	1.958 (1.128–3.400)	0.017
iv	High risk	Yes	25/58	1149	2.968 (1.714–5.142)	< 0.001	2.236 (1.139–4.391)	0.019
		Child–Pugh scoree
①	Low risk	A	21/116	3258	1		1
②	Low risk	B+C	3/13	NA	2.348 (0.947–5.818)	0.065	2.585 (1.038–6.438)	0.041
③	High risk	A	38/100	1386	2.277 (1.348–3.848)	0.002	2.237 (1.296–3.861)	0.004
④	High risk	B+C	6/9	535	2.842 (0.849–9.515)	0.09	2.201 (0.641–7.554)	0.21
		Ishak fibrosis scoref
1	Low risk	0	13/47	3125	1		1
2	Low risk	1/2/3/4/5/6	13/77	NA	0.912 (0.414–2.010)	0.82	1.006 (0.435–2.324)	0.99
3	High risk	0	17/27	660	2.381 (1.123–5.045)	0.024	2.169 (0.977–4.819)	0.057
4	High risk	1/2/3/4/5/6	21/60	1372	1.836 (0.849–3.974)	0.123	2.079 (0.915–4.722)	0.081
		Radical resectiong
11	Low risk	R0	33/169	3125	1		1
22	Low risk	R1+R2+RX	6/14	837	1.308 (0.315–5.423)	0.712	1.501 (0.359–6.280)	0.578
33	High risk	R0	77/154	802	2.430 (1.645–3.589)	<0.001	2.263 (1.482–3.456)	<0.001
44	High risk	R1+R2+RX	11/26	837	4.154 (2.288–7.542)	<0.001	3.081 (1.533–6.191)	0.002

Notes:

^aInformation of tumor stage was unavailable in 24 patients;

^binformation of histologic grade was unavailable in 4 patients;

^cinformation of serum AFP was unavailable in 91 patients;

^dinformation of microvascular invasion was unavailable in 55 patients;

^einformation of Child–Pugh score was unavailable in 130 patients;

^Finformation of Ishak fibrosis score was unavailable in 157 patients;

^ginformation of radical resection was unavailable in 7 patients;

^£adjusted for tumor stage and radical resection.

Abbreviations: AFP, α-fetoprotein; CI, confidence interval; DEMs, differentially expressed microRNAs; HCC, hepatocellular carcinoma; HR, hazard ratio; MST, median survival time; NA, not available; OS, overall survival.